Medicare AdvantageCoverageMedium impact
MA08.045o, Tocilizumab and Related Biosimilars for Intravenous Infusion and Subcutaneous Injection
Independence Blue Cross·Rheumatology, Internal Medicine, Pharmacy·Pharmacy
Effective date
Jan 1, 2026
We identified it
Jun 19, 2026
Summary
Policy MA08.045o updates coverage and medical necessity criteria for Tocilizumab and related biosimilars used for intravenous infusion and subcutaneous injection. This Medicare Advantage policy, effective January 1, 2026, establishes new requirements for when these biologic medications can be covered and reimbursed.
Action Required
By December 15, 2025: Billing team must obtain and review the full policy text from the source URL to identify specific HCPCS codes for Tocilizumab products (likely J-codes), any prior authorization requirements, and medical necessity documentation standards. Update billing software rules, prior authorization workflows, and provider communication templates accordingly. Notify rheumatology, internal medicine, and any other relevant providers of new medical necessity criteria and documentation requirements. Train billing staff on coverage limitations before the January 1, 2026 effective date. Failure to implement required prior auth or documentation requirements will result in claim denials on Medicare Advantage plans.